Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals
Christoph D. Spinner(TUM Klinikum), Gkikas Magiorkinis(National and Kapodistrian University of Athens), Michel Goldman(Université Libre de Bruxelles), Hermann Einsele(Universitätsklinikum Würzburg), Zain Chagla(McMaster University), Walid Kandeil(AstraZeneca (Switzerland)), Dominique Bertrand(Université de Rouen Normandie), Sofie Arnetorp(AstraZeneca (Sweden)), Renata Yokota, Cécile Tremblay(Centre Hospitalier de l’Université de Montréal), Odile Launay(Délégation Paris 5), Samantha James, Sabada Dube(AstraZeneca (United Kingdom)), Carolina Casañas i Comabella(Granta Design (United Kingdom)), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Samira Bell(University of Dundee), Igor Aurer(University Hospital Centre Zagreb), Cécile Artaud(AstraZeneca (France)), Fungwe Jah(AstraZeneca (Germany)), Katarzyna Borkowska(Granta Design (United Kingdom)), Loreto Gesualdo(Unknown), Jacques‐Eric Gottenberg(Hôpitaux Universitaires de Strasbourg), Axel Finckh(University Hospital of Geneva)
Cited by 10
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k